Mantle Cell Lymphoma (MCL) Recruiting Phase 2 Trials for Rituximab (DB00073)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00878254Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell LymphomaTreatment
NCT02339922Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin LymphomaTreatment
NCT03019640Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's LymphomaTreatment
NCT03710772Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaTreatment
NCT01880567Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell LymphomaTreatment
NCT02682641Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCLTreatment